CD1a Antibodies

Structure of CD1a

CD1a is a type I transmembrane glycoprotein with a molecular weight of approximately 33-35 kDa. This molecular weight shows certain differences among different species, mainly due to the degree of glycosylation modification of its extracellular domain and subtle amino acid sequence variations.

This protein is structurally composed of three extracellular domains (α1-α3), a transmembrane region and a short intracellular tail. Its α1 and α2 domains fold to form hydrophobic antigen-binding grooves. This structural feature enables it to bind and present various lipid and glycolipid antigens, which is the core basis of its immune function.

Fig. 1 Postulated mechanisms of CD1a involvement in inflammatory skin disease pathogenesis.¹

Key structural properties of CD1a:

• Unique lipid antigen-binding groove structure
• Mainly made up of two alpha helix hydrophobic binding pocket
• MHC-I folding but with non-polymorphic characteristics
• Transmembrane domains are anchored to the surface of antigen-presenting cells

Functions of CD1a

The main function of the CD1a gene-encoded protein is to present lipid antigens to T cells to initiate adaptive immune responses. In addition, it is also involved in various immune regulatory processes, including the establishment of autoimmune tolerance and the regulation of inflammatory responses.

Unlike the classical MHC molecules that present polypeptide antigens, the CD1a protein specifically presents hydrophobic lipid antigens. This characteristic fills the gap in the immune system's recognition of non-protein antigens and is the uniqueness of its immunological function.

Applications of CD1a and CD1a Antibody in Literature

1. Ye, John H., Yi-Ling Chen, and Graham Ogg. "CD1a and skin T cells: a pathway for therapeutic intervention." Clinical and Experimental Dermatology 49.5 (2024): 450-458. https://doi.org/10.1093/ced/llad460

The article indicates that CD1a is a molecule continuously expressed on skin Langerhans cells, responsible for presenting lipid antigens to T cells and participating in immune surveillance. Studies have shown that the dysregulation of T-cell responses mediated by it is related to the pathogenesis of inflammatory skin diseases such as psoriasis, atopic dermatitis and allergic contact dermatitis.

2. Hardman, Clare S., et al. "CD1a promotes systemic manifestations of skin inflammation." Nature Communications 13.1 (2022): 7535. https://doi.org/10.1038/s41467-022-35071-1

Research has found that the CD1a molecule on the surface of skin Langerhans cells can link local skin inflammation (such as TLR7 agonists or MC903 induction) with systemic immune responses (splenomegaly, T cell expansion and cytokine elevation), and its specific blocking antibodies can effectively inhibit this process.

3. Maeda, Sachiko, et al. "Analysis of CD1a-Positive Monocyte-Derived Cells in the Regional Lymph Nodes of Patients with Gallbladder Cancer." International Journal of Molecular Sciences 25.23 (2024): 12763. https://doi.org/10.3390/ijms252312763

This study of 70 cases of gallbladder cancer found that CD1A-positive dendritic cell infiltration in regional lymph nodes was associated with poor prognosis and lymph node metastasis, but it was not an independent prognostic factor. The infiltration of CD1a cells in the primary tumor lesion has a more significant impact on the surgical outcome.

4. Gulic, Tamara, et al. "Human Decidual CD1a+ Dendritic Cells Undergo Functional Maturation Program Mediated by Gp96." International journal of molecular sciences 24.3 (2023): 2278. https://doi.org/10.3390/ijms24032278

This study shows that the heat shock protein gp96 can dose-dependentially bind to the CD91 and TLR4 receptors of decidual CD1a+ dendritic cells, promoting their maturation and increasing the expression of interferon -γ and IL-15, which may enhance the Th1-type immune response at the maternal-fetal interface and affect the maintenance of pregnancy.

5. Mitchell, Jenée, and George Kannourakis. "Does CD1a expression influence T cell function in patients with langerhans cell histiocytosis?." Frontiers in Immunology 12 (2021): 773598. https://doi.org/10.3389/fimmu.2021.773598

This article explores the possibility that the key lesion marker CD1a+ LCH cells in Langerhans cell histiocytosis (LCH) may be recognized by T cells and thereby participate in the pathogenesis of the disease, and points out that targeting this immune interaction is a potential therapeutic direction.

Creative Biolabs: CD1a Antibodies for Research

Creative Biolabs specializes in the production of high-quality CD1a antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom CD1a Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our CD1a antibodies, custom preparations, or technical support, contact us at email.